See the DrugPatentWatch profile for Dupixent
Dupixent, a monoclonal antibody developed by Sanofi and Regeneron, generates substantial sales across multiple indications. The drug's performance is detailed across its approved uses, though specific sales figures for each indication are not consistently broken out in public financial reports.
What indications is Dupixent approved for?
Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis in adults and children, moderate-to-severe asthma in adults and children, and as an add-on maintenance treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in adults. It is also indicated for eosinophilic esophagitis (EoE) in adults and children aged 12 years and older, and for prurigo nodularis (PN) in adults [1].
How much revenue does Dupixent generate overall?
In the first quarter of 2024, Dupixent reported global sales of approximately $3.1 billion [1]. This represents a notable increase from the previous year, reflecting the drug's growing market penetration and expanded indications.
Which indications are driving Dupixent sales?
While specific sales breakdowns per indication are not always provided, atopic dermatitis has historically been a significant contributor to Dupixent's revenue. The drug's approval for asthma and chronic rhinosinusitis with nasal polyps has also substantially boosted its commercial performance. More recent approvals for eosinophilic esophagitis and prurigo nodularis are expected to further diversify and increase sales [1].
When did Dupixent receive its first approval?
Dupixent received its initial approval from the U.S. Food and Drug Administration (FDA) in March 2017 for the treatment of moderate-to-severe atopic dermatitis [2].
What is the mechanism of action for Dupixent?
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the cytokines interleukin-4 (IL-4) and interleukin-13 (IL-13) [1]. These cytokines are key drivers of type 2 inflammation, which plays a central role in the pathophysiology of diseases like atopic dermatitis, asthma, CRSwNP, EoE, and PN. By blocking these pathways, Dupixent helps to reduce inflammation and associated symptoms [1].
What are the key competitors for Dupixent?
The competitive landscape for Dupixent varies by indication. In atopic dermatitis, it faces competition from other biologic and non-biologic therapies. For asthma, it competes with other biologics targeting type 2 inflammation and other mechanisms. In CRSwNP, EoE, and PN, Dupixent is often a leading therapy with fewer direct biologic competitors approved for the same specific conditions [1].
What are the patent details for Dupixent?
Information on Dupixent's patent exclusivity and expiry dates can be found through resources like DrugPatentWatch.com [3]. These patents are crucial for protecting the drug's market share and influencing the eventual entry of generic or biosimilar versions.
Sources:
[1] Sanofi and Regeneron. (2024). First Quarter 2024 Results. https://www.sanofi.com/en/investors/results-and-presentations
[2] U.S. Food and Drug Administration. (2017). FDA approves Dupixent for adults with moderate-to-severe atopic dermatitis. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-dupixent-adults-moderate-or-severe-atopic-dermatitis
[3] DrugPatentWatch.com. (n.d.). Dupixent Patents. Retrieved from https://drugpatentwatch.com/